Literature DB >> 22680980

Activation of the inflammasome and enhanced migration of microparticle-stimulated dendritic cells to the draining lymph node.

Ismail M Meraz1, Brenda Melendez, Jianhua Gu, Stephen T C Wong, Xuewu Liu, Helen A Andersson, Rita E Serda.   

Abstract

Porous silicon microparticles presenting pathogen-associated molecular patterns mimic pathogens, enhancing internalization of the microparticles and activation of antigen presenting dendritic cells. We demonstrate abundant uptake of microparticles bound by the TLR-4 ligands LPS and MPL by murine bone marrow-derived dendritic cells (BMDC). Labeled microparticles induce concentration-dependent production of IL-1β, with inhibition by the caspase inhibitor Z-VAD-FMK supporting activation of the NLRP3-dependent inflammasome. Inoculation of BALB/c mice with ligand-bound microparticles induces a significant increase in circulating levels of IL-1β, TNF-α, and IL-6. Stimulation of BMDC with ligand-bound microparticles increases surface expression of costimulatory and MHC molecules, and enhances migration of BMDC to the draining lymph node. LPS-microparticles stimulate in vivo C57BL/6 BMDC and OT-1 transgenic T cell interactions in the presence of OVA SIINFEKL peptide in lymph nodes, with intact nodes imaged using two-photon microscopy. Formation of in vivo and in vitro immunological synapses between BMDC, loaded with OVA peptide and LPS-microparticles, and OT-1 T cells are presented, as well as elevated intracellular interferon gamma levels in CD8(+) T cells stimulated by BMDC carrying peptide-loaded microparticles. In short, ligand-bound microparticles enhance (1) phagocytosis of microparticles; (2) BMDC inflammasome activation and upregulation of costimulatory and MHC molecules; (3) cellular migration of BMDC to lymphatic tissue; and (4) cellular interactions leading to T cell activation in the presence of antigen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22680980      PMCID: PMC3524399          DOI: 10.1021/mp3001292

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  53 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

Review 2.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

3.  Expression and localization of IL-1beta mRNA is interrelated with cytoskeletal rearrangement in monocytes stimulated by adherence: a light microscopy in situ hybridization study.

Authors:  U Böcker; O I Sirenko; J S Morris; R B Sartor; M V Singer; J S Haskill; J M Watson
Journal:  Immunol Cell Biol       Date:  2001-10       Impact factor: 5.126

Review 4.  Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Authors:  Dante J Marciani
Journal:  Drug Discov Today       Date:  2003-10-15       Impact factor: 7.851

5.  Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo.

Authors:  R Maldonado-López; T De Smedt; B Pajak; C Heirman; K Thielemans; O Leo; J Urbain; C R Maliszewski; M Moser
Journal:  J Leukoc Biol       Date:  1999-08       Impact factor: 4.962

6.  Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A.

Authors:  Michael Martin; Suzanne M Michalek; Jannet Katz
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Imaging mixed lipid monolayers by dynamic atomic force microscopy.

Authors:  M Deleu; K Nott; R Brasseur; P Jacques; P Thonart; Y F Dufrêne
Journal:  Biochim Biophys Acta       Date:  2001-07-02

8.  Monophosphoryl lipid A activates both human dendritic cells and T cells.

Authors:  Jamila Ismaili; Joëlle Rennesson; Ezra Aksoy; Johan Vekemans; Benoit Vincart; Zoulikha Amraoui; Francois Van Laethem; Michel Goldman; Patrice M Dubois
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

9.  Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

Authors:  Paul Baldrick; Derek Richardson; Gary Elliott; Alan W Wheeler
Journal:  Regul Toxicol Pharmacol       Date:  2002-06       Impact factor: 3.271

Review 10.  Lipid-protein interactions in biological membranes: a structural perspective.

Authors:  A G Lee
Journal:  Biochim Biophys Acta       Date:  2003-05-02
View more
  12 in total

1.  STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity.

Authors:  Sanjay Varikuti; Steve Oghumu; Gayathri Natarajan; Jennifer Kimble; Rachel H Sperling; Ellen Moretti; Mark H Kaplan; Abhay R Satoskar
Journal:  Int Immunol       Date:  2016-08-30       Impact factor: 4.823

Review 2.  Porous silicon advances in drug delivery and immunotherapy.

Authors:  David J Savage; Xuewu Liu; Steven A Curley; Mauro Ferrari; Rita E Serda
Journal:  Curr Opin Pharmacol       Date:  2013-07-08       Impact factor: 5.547

3.  Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns.

Authors:  Jimin Guo; Henning De May; Stefan Franco; Achraf Noureddine; Lien Tang; C J Brinker; Donna F Kusewitt; Sarah F Adams; Rita E Serda
Journal:  Nat Biomed Eng       Date:  2021-11-01       Impact factor: 29.234

Review 4.  Licensing Adaptive Immunity by NOD-Like Receptors.

Authors:  Dong Liu; Anne Marie Rhebergen; Stephanie C Eisenbarth
Journal:  Front Immunol       Date:  2013-12-27       Impact factor: 7.561

Review 5.  Particle platforms for cancer immunotherapy.

Authors:  Rita Elena Serda
Journal:  Int J Nanomedicine       Date:  2013-04-29

6.  Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans.

Authors:  Liam Chung; David R Maestas; Andriana Lebid; Ashlie Mageau; Gedge D Rosson; Xinqun Wu; Matthew T Wolf; Ada J Tam; Isabel Vanderzee; Xiaokun Wang; James I Andorko; Hong Zhang; Radhika Narain; Kaitlyn Sadtler; Hongni Fan; Daniela Čiháková; Claude Jourdan Le Saux; Franck Housseau; Drew M Pardoll; Jennifer H Elisseeff
Journal:  Sci Transl Med       Date:  2020-04-15       Impact factor: 19.319

7.  Mesoporous silicon microparticles enhance MHC class I cross-antigen presentation by human dendritic cells.

Authors:  A Jiménez-Periáñez; B Abos Gracia; J López Relaño; C M Diez-Rivero; P A Reche; E Martínez-Naves; E Matveyeva; M Gómez del Moral
Journal:  Clin Dev Immunol       Date:  2013-11-10

8.  Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes.

Authors:  Ismail M Meraz; Claire H Hearnden; Xuewu Liu; Marie Yang; Laura Williams; David J Savage; Jianhua Gu; Jessica R Rhudy; Kenji Yokoi; Ed C Lavelle; Rita E Serda
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

9.  Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines.

Authors:  Charles M Lundquist; Christopher Loo; Ismail M Meraz; Jorge De La Cerda; Xuewu Liu; Rita E Serda
Journal:  Med Sci (Basel)       Date:  2014-02-20

10.  Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer.

Authors:  Ismail M Meraz; David J Savage; Victor Segura-Ibarra; Jeffrey Li; Jessica Rhudy; Jianhua Gu; Rita E Serda
Journal:  Mol Pharm       Date:  2014-09-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.